uniQure N.V. Selling, General and Administrative Expense
uniQure N.V. (QURE) reported Selling, General and Administrative Expense of $20.07 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-05-05
- uniQure N.V. selling, general and administrative expense for the quarter ending 2026-03-31 was $20.07M, a 83.98% increase year-over-year.
- uniQure N.V. selling, general and administrative expense for the quarter ending 2025-12-31 was $21.61M, a 89.93% increase year-over-year.
- uniQure N.V. selling, general and administrative expense for the quarter ending 2025-09-30 was $19.44M, a 67.93% increase year-over-year.
- uniQure N.V. selling, general and administrative expense for the quarter ending 2025-06-30 was $13.50M, a 14.38% decline year-over-year.
- uniQure N.V. selling, general and administrative expense for fiscal 2025 was $65.46M, a 24.31% increase from fiscal 2024.
- uniQure N.V. selling, general and administrative expense for fiscal 2024 was $52.66M, a 29.41% decline from fiscal 2023.
- uniQure N.V. selling, general and administrative expense for fiscal 2023 was $74.59M, a 35.47% increase from fiscal 2022.
- uniQure N.V. selling, general and administrative expense for fiscal 2022 was $55.06M, a 2.19% decline from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-03-31 | $20.07M 10-Q · filed 2026-05-05 | $41.68M derived: sum of 2 quarters · filed 2026-05-05 | $61.12M derived: sum of 3 quarters · filed 2026-05-05 | $74.62M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $21.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $41.05M derived: sum of 2 quarters · filed 2026-03-02 | $54.55M derived: sum of 3 quarters · filed 2026-03-02 | $65.46M 10-K · filed 2026-03-02 |
| 2025-09-30 | $19.44M 10-Q · filed 2025-11-10 | $32.94M derived: sum of 2 quarters · filed 2025-11-10 | $43.85M 10-Q · filed 2025-11-10 | $55.22M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $13.50M 10-Q · filed 2025-07-29 | $24.41M 10-Q · filed 2025-07-29 | $35.79M derived: sum of 3 quarters · filed 2026-05-05 | $47.36M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $10.91M 10-Q · filed 2026-05-05 | $22.29M derived: sum of 2 quarters · filed 2026-05-05 | $33.86M derived: sum of 3 quarters · filed 2026-05-05 | $49.63M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $11.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $22.95M derived: sum of 2 quarters · filed 2026-03-02 | $38.72M derived: sum of 3 quarters · filed 2026-03-02 | $52.66M 10-K · filed 2026-03-02 |
| 2024-09-30 | $11.57M 10-Q · filed 2025-11-10 | $27.34M derived: sum of 2 quarters · filed 2025-11-10 | $41.28M 10-Q · filed 2025-11-10 | $58.77M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $15.77M 10-Q · filed 2025-07-29 | $29.70M 10-Q · filed 2025-07-29 | $47.19M derived: sum of 3 quarters · filed 2026-03-02 | $65.27M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $13.94M 10-Q · filed 2025-05-09 | $31.43M derived: sum of 2 quarters · filed 2026-03-02 | $49.50M derived: sum of 3 quarters · filed 2026-03-02 | $70.68M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $17.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $35.56M derived: sum of 2 quarters · filed 2026-03-02 | $56.74M derived: sum of 3 quarters · filed 2026-03-02 | $74.59M 10-K · filed 2026-03-02 |
| 2023-09-30 | $18.07M 10-Q · filed 2024-11-05 | $39.26M derived: sum of 2 quarters · filed 2024-11-05 | $57.10M 10-Q · filed 2024-11-05 | $75.36M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $21.18M 10-Q · filed 2024-08-01 | $39.03M 10-Q · filed 2024-08-01 | $57.29M derived: sum of 3 quarters · filed 2025-02-27 | $70.61M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $17.85M 10-Q · filed 2024-05-07 | $36.10M derived: sum of 2 quarters · filed 2025-02-27 | $49.43M derived: sum of 3 quarters · filed 2025-02-27 | $61.92M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $18.26M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $31.58M derived: sum of 2 quarters · filed 2025-02-27 | $44.07M derived: sum of 3 quarters · filed 2025-02-27 | $55.06M 10-K · filed 2025-02-27 |
| 2022-09-30 | $13.32M 10-Q · filed 2023-11-07 | $25.82M derived: sum of 2 quarters · filed 2023-11-07 | $36.80M 10-Q · filed 2023-11-07 | $50.77M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $12.49M 10-Q · filed 2023-08-01 | $23.48M 10-Q · filed 2023-08-01 | $37.45M derived: sum of 3 quarters · filed 2024-02-28 | $49.47M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $10.99M 10-Q · filed 2023-05-09 | $24.95M derived: sum of 2 quarters · filed 2024-02-28 | $36.98M derived: sum of 3 quarters · filed 2024-02-28 | $54.28M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $13.97M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $25.99M derived: sum of 2 quarters · filed 2024-02-28 | $43.29M derived: sum of 3 quarters · filed 2024-02-28 | $56.29M 10-K · filed 2024-02-28 |
| 2021-09-30 | $12.02M 10-Q · filed 2022-11-02 | $29.32M derived: sum of 2 quarters · filed 2022-11-02 | $42.32M 10-Q · filed 2022-11-02 | $52.91M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $17.30M 10-Q · filed 2022-08-08 | $30.30M 10-Q · filed 2022-08-08 | $40.88M derived: sum of 3 quarters · filed 2023-02-27 | $51.67M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $12.38M 10-Q · filed 2022-05-02 | $23.58M derived: sum of 2 quarters · filed 2023-02-27 | $34.37M derived: sum of 3 quarters · filed 2023-02-27 | $45.88M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $11.21M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $22.00M derived: sum of 2 quarters · filed 2023-02-27 | $33.51M derived: sum of 3 quarters · filed 2023-02-27 | $42.58M 10-K · filed 2023-02-27 |
| 2020-09-30 | $10.79M 10-Q · filed 2021-10-25 | $22.30M derived: sum of 2 quarters · filed 2021-10-25 | $31.37M 10-Q · filed 2021-10-25 | $40.05M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $11.51M 10-Q · filed 2021-07-26 | $20.58M 10-Q · filed 2021-07-26 | $29.26M derived: sum of 3 quarters · filed 2022-02-25 | $38.19M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $9.07M 10-Q · filed 2021-05-10 | $17.75M derived: sum of 2 quarters · filed 2022-02-25 | $26.68M derived: sum of 3 quarters · filed 2022-02-25 | $34.55M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $8.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $17.61M derived: sum of 2 quarters · filed 2022-02-25 | $25.48M derived: sum of 3 quarters · filed 2022-02-25 | $33.54M 10-K · filed 2022-02-25 |
| 2019-09-30 | $8.93M 10-Q · filed 2020-10-27 | $16.80M derived: sum of 2 quarters · filed 2020-10-27 | $24.87M 10-Q · filed 2020-10-27 | $32.08M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $7.87M 10-Q · filed 2020-07-30 | $15.94M 10-Q · filed 2020-07-30 | $23.15M derived: sum of 3 quarters · filed 2021-03-01 | $29.05M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $8.07M 10-Q · filed 2020-04-29 | $15.28M derived: sum of 2 quarters · filed 2021-03-01 | $21.18M derived: sum of 3 quarters · filed 2021-03-01 | $27.07M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $7.21M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $13.11M derived: sum of 2 quarters · filed 2021-03-01 | $19.00M derived: sum of 3 quarters · filed 2021-03-01 | $25.30M 10-K · filed 2021-03-01 |
| 2018-09-30 | $5.90M 10-Q · filed 2019-10-28 | $11.79M derived: sum of 2 quarters · filed 2019-10-28 | $18.09M 10-Q · filed 2019-10-28 | $25.38M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $5.90M 10-Q · filed 2019-07-29 | $12.20M 10-Q · filed 2019-07-29 | $19.48M derived: sum of 3 quarters · filed 2020-03-02 | $25.06M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $6.30M 10-Q · filed 2019-04-29 | $13.58M derived: sum of 2 quarters · filed 2020-03-02 | $19.17M derived: sum of 3 quarters · filed 2020-03-02 | $24.58M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $7.28M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $12.87M derived: sum of 2 quarters · filed 2020-03-02 | $18.28M derived: sum of 3 quarters · filed 2020-03-02 | $24.64M 10-K · filed 2020-03-02 |
| 2017-09-30 | $5.58M 10-Q · filed 2018-11-06 | $10.99M derived: sum of 2 quarters · filed 2018-11-06 | $17.35M 10-Q · filed 2018-11-06 | $23.11M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-06-30 | $5.41M 10-Q · filed 2018-08-08 | $11.77M 10-Q · filed 2018-08-08 | $17.52M derived: sum of 3 quarters · filed 2019-02-28 | $22.64M derived: sum of 4 quarters · filed 2019-02-28 |
| 2017-03-31 | $6.36M 10-Q · filed 2018-04-30 | $12.11M derived: sum of 2 quarters · filed 2019-02-28 | $17.23M derived: sum of 3 quarters · filed 2019-02-28 | $25.06M derived: sum of 4 quarters · filed 2019-02-28 |
| 2016-12-31 | $5.75M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $10.87M derived: sum of 2 quarters · filed 2019-02-28 | $18.70M derived: sum of 3 quarters · filed 2019-02-28 | $26.00M 10-K · filed 2019-02-28 |
| 2016-09-30 | $5.11M 10-Q · filed 2017-11-01 | $12.95M derived: sum of 2 quarters · filed 2017-11-01 | $20.25M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $7.83M 10-Q · filed 2017-08-08 | $15.13M 10-Q · filed 2017-08-08 | ||
| 2016-03-31 | $7.30M 10-Q · filed 2017-05-09 | |||
| 2015-12-31 | $23.38M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $17.07M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |